Shattuck Labs, Inc. (STTK) announced on Monday that the FDA has granted orphan drug designation to their primary clinical candidate SL-172154 for treating Acute Myeloid Leukemia or AML.
The company also expects to share further data from the Phase 1B dose expansion clinical trial of SL-172154 with azacitidine in frontline higher-risk myelodysplastic syndromes and TP53m AML patients at a poster presentation at the European Hematology Association 2024 Congress.
Acute Myeloid Leukemia is a form of cancer affecting the blood and bone marrow characterized by an overabundance of immature white blood cells.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.